Corcept Therapeutics Inc
CORT
Market Cap$2.35B
Close$
$65.50
191.3% upside
Current Fair Value
191.3% upsideUndervalued by 191.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.35 Billion |
|---|---|
| Enterprise Value | $1.98 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $0.95 |
| Beta | 1.01 |
| Outstanding Shares | 103,520,000 |
| Avg 30 Day Volume | 768,857 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 22.1 |
|---|---|
| PEG | 24.87 |
| Price to Sales | 5.62 |
| Price to Book Ratio | 5.62 |
| Enterprise Value to Revenue | 4.1 |
| Enterprise Value to EBIT | 18.43 |
| Enterprise Value to Net Income | 18 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
ESG Score
No data
About Corcept Therapeutics Inc
CEO: Joseph Belanoff Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved...